Cardiovascular Disease Risk After Treatment-Induced Premature Ovarian Insufficiency in Female Survivors of Hodgkin Lymphoma.
Cardiovascular Disease Risk After Treatment-Induced Premature Ovarian Insufficiency in Female Survivors of Hodgkin Lymphoma.
复制标题
DOI:
10.1016/j.jacc.2018.10.030
复制
发表时间:
2018-12
影响因子:
24
通讯作者:
I. Krul;Annemieke W. J. Opstal-van Winden;C. Janus;L. Daniëls;Y. Appelman;A. Maas;S. de Vries;K. Jóźwiak;B. Aleman;F. V. van Leeuwen
中科院分区:
文献类型:
--
作者:
I. Krul;Annemieke W. J. Opstal-van Winden;C. Janus;L. Daniëls;Y. Appelman;A. Maas;S. de Vries;K. Jóźwiak;B. Aleman;F. V. van Leeuwen
Please note: The study was supported by an unrestricted grant form Medtronic Inc. to the University of Erlangen-Nürnberg. Dr. Mahfoud is supported by Deutsche Hochdruckliga, Deutsche Gesellschaft für Kardiologie, and Deutsche Forschungsgemeinschaft (SFB TRR 219). Dr. Böhm is supported by Deutsche Gesellschaft für Kardiologie and Deutsche Forschungsgemeinschaft (SFB TRR 219). Dr. Mahfoud has received speaker honoraria from Medtronic and ReCor. Dr. Böhm has received speaker honoraria from Servier, Boehringer Ingelheim, Vifor, and Novartis; and research grants from Medtronic, AstraZeneca, AMGEN, Cytokinetics, BMS, Novartis, and Boehringer Ingelheim. Dr. Schmieder has received extramural research funding from and has been an advisor and speaker for Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors acknowledge the excellent work done by the study nurses and cath lab personal of both centers of the University Hospital Erlangen and Saarland University Hospital.